Kaleido BioSciences
Bedford
About Kaleido BioSciences
Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health. The Company has built a human-centric proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $230.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2021)
- Ticker: nasdaq:KLDO
- Website: kaleido.com
- Phone: (617)674-9000
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/kaleido-biosciences-198432 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.